Neotract touts coverage win for UroLift prostate device
NeoTract said today it won coverage for its Urolift system from Medicare Administrative Contractor First Coast Service Options.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
First Coast Service Options covers Florida, Puerto Rico and the U.S. Virgin Islands, the Pleasanton, Calif.-based company said.
“We are thrilled that millions of men across the United States now have access to the UroLift System treatment. The recently published four-y...
Source: Mass Device - November 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Source Type: news
Benign Prostatic Hyperplasia (BPH) Treatment Should Be Individualized...
BPH affects approximately 50% of men between the ages of 51 - 60 & up to 90% of men over the age of 80. Men need to work with their doctor to determine which treatment option is right for them.(PRWeb October 04, 2016)Read the full story at http://www.prweb.com/releases/BPH_Enlarged_Prostate/David_Samadi/prweb13732813.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 4, 2016 Category: Pharmaceuticals Source Type: news
NeoTract touts reimbursement win for UroLift
NeoTract today touted a reimbursement win from Geisinger Health Plan and EmblemHealth that will allow coverage for procedures using its UroLift system for patients with benign prostatic hyperplasia.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
Geisinger Health Plan serves 540,000 members in Pennsylvania, New Jersey, Delaware, Main and West Virginia, while EmblemHealth serves New York, New Jersey and Connecticut.
“We are pleased to see the...
Source: Mass Device - October 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology NeoTract Source Type: news
BPH Drugs Don't Independently Raise the Risk of ED: Study BPH Drugs Don't Independently Raise the Risk of ED: Study
A large observational study finds no evidence that use of 5-alpha-reductase inhibitors for benign prostatic hyperplasia (BPH) or alopecia raise the risk of erectile dysfunction.Reuters Health Information (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 29, 2016 Category: Urology & Nephrology Tags: Urology News Source Type: news
National Prostate Cancer Awareness Month -- Educating All Men On Reducing Their Risk
This study only looked at the effect of dietary or food sources of zinc and not at zinc supplements. Some dietary sources of zinc include the following:
• Beef steak - 3 oz contains 4.9 mg
• Oysters - 3 oz contains 67 mg
• Shrimp - 3 oz contains 1.5 mg
• Pork chop - 3 oz contains 2.8 mg
• Yogurt - 1 cup contains 2.2 mg
• Enriched cereal - ¾ cup contains 15 mg
• Red kidney beans - ½ cup contains 2 mg
Zinc coming from meat sources is more readily bioavailable than zinc from vegetarian sources. Legumes and whole grains contain phytic acid inhibiting zinc's bioavailability.
Consult with your doctor for their ...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news
Finasteride, Dutasteride Don't Seem to Increase Risk for Erectile Dysfunction (FREE)
By Amy Orciari Herman
Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS
The 5-alpha reductase inhibitors finasteride and dutasteride do not appear to increase risk for erectile dysfunction in men with benign prostatic hyperplasia … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 22, 2016 Category: Primary Care Source Type: news
Ultrasound Noninvasively Detects Bladder Outlet Obstruction Ultrasound Noninvasively Detects Bladder Outlet Obstruction
Bladder and prostate ultrasonography noninvasively detects bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia (BPH), researchers from Saudi Arabia report.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 21, 2016 Category: Radiology Tags: Urology News Source Type: news
Audax deals Laborie Medical to Patricia Industries
Private equity player Audax Group said today it sold Laborie Medical Technologies to Investor AB subsidiary Patricia Industries for an undisclosed amount.
Toronto-based Laborie Medical Tech develops and manufactures urological, pelvic health and gastrointestinal medical devices used for diagnosis and treatment of urinary incontinence and other urological and GI conditions, Audax Medical said.
Laborie acquired the pelvic muscle rehabilitation business of UroMed Technology in October 2013 for an undisclosed amount.
“Under Audax’ ownership, Laborie transformed from a manufacturer of capital equipment for urodynamic...
Source: Mass Device - September 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Mergers & Acquisitions Urology Wall Street Beat Audax Group Laborie Medical Technologies Source Type: news
Enlarged prostate: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, we hear from Dr. Amy Krambeck about enlarged prostates, a condition know as benign prostatic hyperplasia.. To listen, click the link below. Enlarged Prostate (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 15, 2016 Category: Databases & Libraries Source Type: news
Medical News Today: Enlarged prostate: Molecular mechanism clue may explain link to inflammation
Discovery of molecular mechanism may explain how inflammation leads to benign prostatic hyperplasia and improve response to androgen-targeted therapies. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2016 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Serendipitous finding leads scientists to propose mechanism to explain benign prostatic hyperplasia
Benign prostatic hyperplasia affects about half of men between 51 and 60 years of age, and nine out of 10 men older than 80. How BPH happens, however, is still open for debate. A new report outlines a new mechanism that can explain the development of BPH and suggest strategies to improve the response to androgen-targeting therapies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 1, 2016 Category: Science Source Type: news
Serendipitous finding leads scientists to propose mechanism to explain benign prostatic hyperplasia
(Baylor College of Medicine) Benign prostatic hyperplasia affects about half the men between 51 and 60 years of age, and nine out of 10 men older than 80. How BPH happens, however, is still open for debate. In a paper published today in Molecular Cell, researchers at Baylor College of Medicine and other institutions report a new mechanism that can explain the development of BPH and suggest strategies to improve the response to androgen-targeting therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 1, 2016 Category: Cancer & Oncology Source Type: news
Button TURP vs. Green Light Laser for Benign Prostatic Hyperplasia -...
Button TURP and Green Light Laser are less invasive prostate surgeries used to treat BPH, a condition that affects 50% of men in their 50s and as many as 90% by the time a man reaches his 70s, or...(PRWeb August 10, 2016)Read the full story at http://www.prweb.com/releases/Dr_David_Samadi/BPH/prweb13605293.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2016 Category: Pharmaceuticals Source Type: news
Many Commonly Used Drugs Are Useless
Some medications are life saving. I am so thankful for the trusty med that tames my atrial fibrillation.
Many meds are helpful -- demonstrating superiority to placebo in ways that are clearly clinically significant and life enhancing.
But many (perhaps most) drugs are probably no more than very expensive placebos. Patients get prescriptions from doctors when their symptoms are most severe and improve with time and positive expectation, not because the med is really effective.
Doctors and patients need independent, objective information on drug efficacy and risks.
The multibillion dollar pharma marketing machine can tu...
Source: Science - The Huffington Post - August 7, 2016 Category: Science Source Type: news
Medi-Tate wins strategic investment from Canada’s Laborie Medical Technologies
Laborie Medical Technologies said it took out a stake in Israel’s Medi-Tate, which is developing devices to treat enlarged prostates, for an unspecified amount.
Toronto-based Laborie, which is owned by private equity company Audax Group, in October 2013 acquired the pelvic muscle rehabilitation business of UroMed Technology, also for an undisclosed amount.
Akiva, Israel-based Medi-Tate developed a minimally invasive treatment for benign prostate hyperplasia called iTind, which uses a 5-day implant to reshape the urethra and create new channels for urine flow. It’s designed to lower the risk of post-proce...
Source: Mass Device - July 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat Laborie Medical Technologies Medi-tate Ltd. Source Type: news
